分子靶向药物联合核转录因子kβ抑制剂对胃癌细胞系SNU-1的抑制作用

Growth inhibition of gastric cancer cell lines SNU-1 induced by molecular targeted drug combined with NF-kβ inhibitor

目的探讨索拉菲尼、拉帕替尼联合吡咯烷二硫代氨基甲酸盐(PDTC)对胃癌细胞系SNU-1的增殖、凋亡及细胞周期的影响。方法实验分3大组,分别为空白组、实验组和对照组:空白组(A组),加细胞,再加相应等量的培养基,不加干预药物;实验组再分4组(B、C、D、E组),3.0μmol·L-1索拉菲尼加3.0μmol·L-1拉帕替尼(B组),3.0μmol·L-1索拉菲尼加50.0μmol·L-1PDTC(C组),3.0μmol·L-1拉帕替尼再加50.0μmo·L-1PDTC(D组),3.0μmol·L-1的索拉菲尼加3.0μmol·L-1的拉帕替尼加50μmol·L-1的PDTC(E组);对照组再分3组,分别用低、中、高3种不同浓度的索拉菲尼、拉帕替尼(1.5,6.0,12.0μmol·L-1)和PDTC(25.0,100.0,200.0μmol·L-1)做对照。用MTT法分别检测不用药物组的抑制作用,用流式细胞仪检测各组药物对胃癌细胞周期和细胞凋亡的影响。结果不同药物组对SNU-1都有一定的抑制作用,3种药物联合作用能显著抑制细胞生长(P<0.05),显著影响细胞周期(P<0.05),显著提高细胞的凋亡率(P<0.05)。结论 3种药物联合可以有效地抑制胃癌细胞的增殖。

Objective To investigate the influence on proliferation, apoptosis and cell cycle of gastric cancer cell lines SNU-1 induced by molecular targeted drug sorafenib and lapatinib combined with ammonium pyrrolidinedithiocarbamate （ PDTC）.Methods Groups were divided as follows：blank group （ A group ） , fore test groups, include B group, sorafenib＋lapatinib（3,3μmol· L-1, respectively）,C group, sorafenib＋PDTC（3,50 μmol· L-1,respectively）,D group, lapatinib ＋PDTC（3, 50 μmol· L-1 , respectively ） , and E group, sorafenib ＋lapatinib ＋PDTC（3,3,50 μmol· L-1 ,respectively） and three different concentra-tions of sorafenib and lapatinib （ 1.5 , 6.0 , 12.0 μmol· L-） , PDTC （25,100,200 μmol· L-1 ） as control groups, respectively.The inhibi-tion of gastric cell line SNU-1 was detected by MTT.The cell cycle and apoptosis were disclosed by flow cytometry, respectively.Results There were some certain inhibition of gastric cancer cell line SNU-1 induced by different groups.The differences had significantly in three drugs combi-nation groups on the rate of cell inhibition, the S-phase cells decreased, and increased apoptosis （ all P 〈0.05 ） . Conclusion Combining with three drugs can effectively inhibit the proliferation and induce apoptosis of gastric cancer cell SNU-1.